News and Press Releases
RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib
Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib 26 March 2025 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson &...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 26, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
25 March 2025 -- Massachusetts, US, and Gosselies, Belgium -- iTeos Therapeutics, Inc, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe
25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD 2025 Conference
Data show positive impact of small molecule GAL-201 on Aβ-induced toxicity, caused by various Aβ isoforms: beneficial effects on synaptic plasticity and neuroinflammation 24 March 2025 -- Maryland, US and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001
Updates to HEALEY ALS Platform Trial Master Protocol have been made to enhance the potential of establishing a clinically meaningful outcome for patients, including: Treatment period extended from 24 to...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
First and only EZH2 inhibitor approved by the NMPA HUTCHMED’s fourth product, and its first approval in hematological malignancies. 21 March 2025 -- Hong Kong, Shanghai & New Jersey, US...
Category:
Posted: March 21, 2025
FLAMOD against respiratory infections: phase I clinical trial of innovative new drug begins
20 March 2025 -- Lausanne, Switzerland -- A phase I clinical trial for a groundbreaking therapeutic innovation against respiratory infections has begun at the Clinical Investigation Centre of the Academic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 20, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials
This investment will improve the healthcare experience for patients, reinforcing Dassault Systèmes’ role in the industry’s transformation Click Therapeutics will gain access to Dassault Systèmes’ global presence and expertise to...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 19, 2025
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
19 March 2025 -- Hong Kong, Shanghai & New Jersey, US -- HUTCHMED (China) Limited and Innovent Biologics, Inc, today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2025
SolasCure enrols first patient in a next Phase II clinical trial to advance Aurase Wound Gel
Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers 17 March 2025 -- Cambridge,...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: March 17, 2025
